

Published in final edited form as:

Nat Rev Mol Cell Biol. ; 13(4): 225–238. doi:10.1038/nrm3293.

Sirtuins as regulators of metabolism and healthspan

Riekelt H. Houtkooper^{#1,\$}, Eija Pirinen^{#1,2}, and Johan Auwerx^{1,#}

¹Laboratory for Integrative and Systems Physiology, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland ²Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, Biocenter Kuopio, University of Eastern Finland, Kuopio, Finland

[#] These authors contributed equally to this work.

Preface

Since the beginning of the century, the mammalian sirtuin protein family (SIRT1–SIRT7), has received much attention for their regulatory role, mainly in metabolism and aging. Sirtuins act in different cellular compartments: they deacetylate histones and several transcriptional regulators in the nucleus, but also specific proteins in other cellular compartments, such as in the cytoplasm and in mitochondria. As a consequence, sirtuins regulate fat and glucose metabolism in response to physiological changes in energy levels, thereby acting as crucial regulators of the network that controls energy homeostasis, and as such determines healthspan.

Keywords

Aging; Longevity; Metabolic disease; Mitochondria; Resveratrol; Sirtuins

Metabolic control involves a delicate balance between energy intake, utilization and storage. When food is ample, the excess energy is stored so that it can be used in times of scarcity. A carefully tuned regulatory and evolutionary conserved programme controls these switches in nutrient intake, use and storage, involving classical food excess signaling pathways, such as those revolving around insulin/IGF1 and target of rapamycin (TOR; mTOR in mammals), and food restriction pathways involving AMP-activated protein kinase (AMPK) and sirtuins (for further reading on these pathways, we refer the reader to refs 1–4).

Sirtuins have received significant attention since the discovery that the yeast sirtuin silent information regulator 2 (Sir2), which was originally described as a regulator of transcriptional silencing of mating-type loci, telomeres and ribosomal DNA (reviewed in 5,6), extends yeast lifespan⁷. As Sir2 was soon discovered to be an NAD-dependent histone deacetylase⁸, it became apparent that sirtuins serve both as energy sensors and as transcriptional effectors by controlling the acetylation state of histones. What is more, sirtuins do not just deacetylate histones, but also a wide range of transcriptional regulators, thereby controlling their activity.

[#]To whom correspondence should be addressed: admin.auwerx@epfl.ch.

^{\$}Current address: Laboratory Genetic Metabolic Diseases, University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands

In mammals the sirtuin family comprises seven proteins (SIRT1-SIRT7), which vary in tissue specificity, subcellular localization, enzymatic activity and targets. Sirtuins, notably SIRT1, have been studied for their role in caloric restriction (the only physiological intervention that extends lifespan), the prevention of aging-related diseases and the maintenance of metabolic homeostasis. As a consequence, the hunt for nutraceutical (obtained through food) or pharmaceutical sirtuin activators was intense and led to the identification of several sirtuin activator compounds. Especially resveratrol, a polyphenol found in red grapes, berries and peanuts, received a lot of attention⁹. Activation of sirtuins is thought to be beneficial not only for diseases relating to metabolism, such as type 2 diabetes and obesity, but also for neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. This is in part because sirtuins stimulate the activity of mitochondria, the powerhouses of the cell, and of mitochondrial proteins, which have a key role in the above-mentioned pathologies.

Here we present our current knowledge of the sirtuin family, discussing their mode of action, function and regulation. We focus primarily on SIRT1, as it is the best described sirtuin, and place particular focus on the impact of sirtuins on metabolic homeostasis and healthspan.

The sirtuin family

Sequence-based phylogenetic analysis revealed that mammalian sirtuins can be divided in four classes: SIRT1-SIRT3 belong to class I, SIRT4 to class II, SIRT5 to III, and SIRT6 and SIRT7 to class IV¹⁰. Below we discuss the subcellular localization of sirtuins, their mode of action and their functions in different compartments.

Sirtuin subcellular localization

Mammalian sirtuins show a discrete pattern of subcellular localization. SIRT1 is mainly localized in the nucleus, but also is present in the cytosol. Its nuclear export signal allows shuttling to the cytosol under specific circumstances, for instance when the insulin pathway is pharmacologically inhibited¹¹. Although the physiological relevance of this shuttling is unclear, one can imagine that either cytosolic targets could be deacetylated, or that shuttling is another level of control on nuclear target proteins. SIRT2 is considered to be cytosolic, but is also present in the nucleus in the G2/M cell cycle transition¹². SIRT3, SIRT4, and SIRT5 all have a mitochondrial targeting sequence, and their localization to this organelle has been confirmed experimentally¹³. SIRT6 is predominantly nuclear¹⁴, and SIRT7 was reported to reside in the nucleolus¹⁵, but further research is necessary to confirm this localization and its physiological relevance.

Sirtuin enzymatic activity

Originally, sirtuins were described as NAD-dependent type III histone deacetylases (HDACs), as the founding sirtuin — Sir2 in yeast — silenced specific genomic loci by deacetylating histone H3 and H4¹⁶. Interestingly, mammalian sirtuins — notably those in class I — do not only target histones, but also deacetylate a wide array of proteins in different subcellular compartments (see above; Box 1). In addition, SIRT4¹⁷ and SIRT6¹⁸ were reported to function as ADP-ribosyltransferases, even though SIRT6 also can act as a

deacetylase^{19,20}. SIRT5 was initially reported to deacetylate the urea cycle enzyme carbamoyl phosphate synthetase 1 (CPS1)²¹, but was recently shown to primarily demalonylate and desuccinylate proteins²², including CPS1²³ (Box 1).

The enzymatic reaction catalyzed by sirtuin proteins requires NAD⁺ as a substrate, which is converted to nicotinamide, and the concentration of which is determined by the nutritional state of the cell²⁴. As such, NAD⁺ is well positioned to control adaptive responses to energy stress by modulating the activity of sirtuins and their downstream effectors, as will be discussed below.

During the sirtuin enzymatic reaction, nicotinamide is formed, which at higher concentrations can non-competitively bind and thereby feedback-inhibit sirtuin activity^{25,26}. The other by-product of the sirtuin deacetylase reaction — O-acetyl-ADP-ribose — was also reported to be a signaling molecule^{27,28}, but similarly to nicotinamide, its exact role in metabolic control warrants further investigation (for details see 24,29).

Sirtuin function — SIRT1

The most-studied member of the mammalian sirtuin family is SIRT1, which was originally described to deacetylate histones, but soon after also shown to deacetylate other protein targets (Table 1)(see 5,30,31 for more details). The first-described non-histone target for SIRT1 was p53, which is deacetylated and repressed upon DNA damage or oxidative stress, resulting in impaired apoptosis^{32,33}. It was therefore hypothesized that increased SIRT1 activity could be tumorigenic, but the contrary seems to be the case (reviewed in 34). The activity of PGC1 α , a transcriptional coregulator that governs mitochondrial biogenesis and activity, is also controlled by reversible acetylation^{35,36}. PGC1 α deacetylation by SIRT1 leads to its activation and the induction of downstream pathways that control mitochondrial gene expression^{37–42}. Similarly, SIRT1 controls the acetylation of FOXO transcription factors, which are important regulators of lipid and glucose metabolism as well as stress response (see below). It is thought that SIRT1-mediated deacetylation does not just activate or inhibit FOXO, but it selectively directs FOXO to certain targets, thereby conferring another layer of specificity in addition to regulation by phosphorylation (see below)^{43–45}.

Sirtuin function — SIRT3

Three sirtuins localize primarily to the mitochondria—SIRT3-SIRT5 (for recent reviews see 46,47). Of these, SIRT3 is the major mitochondrial deacetylase⁴⁸, and several of its targets have been identified. For example, LCAD — a protein involved in fatty acid oxidation — is a prime target for SIRT3 deacetylation during prolonged fasting, resulting in the activation of fatty acid breakdown⁴⁹. As a result, deletion of *Sirt3* impairs fat breakdown, exacerbating diet-induced obesity, and rendering these mice cold sensitive upon fasting⁵⁰. The role for SIRT3 in fasting was further confirmed by the identification of multiple SIRT3 deacetylation sites in the enzyme 3-hydroxy-3-methylglutaryl CoA synthase 2, which regulates the production of ketone bodies, an important energy source for the brain when blood glucose levels are low⁵¹. An additional level of metabolic control by SIRT3 involves CR-induced deacetylation and activation of isocitrate dehydrogenase 2 (which is involved in the TCA

cycle)⁵², and deacetylation of components of complexes I⁵³, II⁵⁴ and III⁵⁵ of oxidative phosphorylation, the final stage of mitochondrial aerobic respiration.

More recently, it became apparent that SIRT3 also affects oxidative stress defense, protecting the cell from reactive oxygen species (ROS) that are a by-product of oxidative phosphorylation^{52,55,56}. Indeed, during caloric restriction, SIRT3 activates superoxide dismutase 2 (SOD2)⁵⁶, a key mitochondrial antioxidant enzyme. Additionally, CR induces the SIRT3-mediated deacetylation of isocitrate dehydrogenase 2 in various tissues including inner ear cells, and thereby increases the ratio of reduced to oxidized glutathione, attenuating ROS levels⁵². As a result, CR protects against age-related hearing loss in a *Sirt3*-dependent fashion⁵².

SIRT3 also deacetylates and activates glutamate dehydrogenase (GDH)^{48,57}, an enzyme controlling the TCA cycle, but the physiological relevance of this process is unclear. Finally, it is important to realize that most data regarding SIRT3 function are derived from the analysis of germline *Sirt3*^{-/-} mice and studies in somatic *Sirt3*^{-/-} mice will be necessary to address tissue contributions.

Sirtuin function — other sirtuins

Compared to SIRT1 and SIRT3, not much is known about the physiology of the other sirtuins. The cytosolic SIRT2 deacetylates tubulin⁵⁸, but the relevance of this is unclear. More importantly, SIRT2 also deacetylates PAR-3, which in turn decreases the activity of the cell polarity control protein atypical protein kinase C (aPKC), thereby changing myelin formation of Schwann cells⁵⁹. Additionally, in glucose-deprived conditions SIRT2 deacetylates phosphoenolpyruvate carboxykinase (PEPCK), which is involved in gluconeogenesis; this stabilizes the protein and prevents its ubiquitinylation-dependent degradation⁶⁰. SIRT2 was also shown to deacetylate and activate FOXO1 impacting as such on adipogenesis⁶¹. The mitochondrial SIRT4, ADP-ribosylates GDH, inhibiting its activity and blocking amino acid-induced insulin secretion¹⁷. As a consequence, *Sirt4*^{-/-} mice have increased plasma insulin levels, both in fed and fasted state, and when stimulated with glutamine¹⁷. SIRT4 also regulates fatty acid oxidation in hepatocytes and myocytes, and shRNA-mediated *Sirt4* knockdown in liver increased fatty acid oxidation⁶². It is interesting to note that SIRT3 and SIRT4 have apparently opposing roles in the regulation of GDH^{17,48,57} and fatty acid oxidation^{49,62}, which will require further study to define how these two NAD⁺-dependent enzymes integrate similar nutrient states into divergent responses.

The only target described for SIRT5 is CPS1, whose deacetylation during fasting activates ammonia detoxification through the urea cycle²¹. The primary function of SIRT5, however, may not act as a deacetylase²¹, but rather as a demalonylase and desuccinylase²², even of the described deacetylase target CPS1²³. Future studies will have to determine whether SIRT5 indeed has deacetylase activity in vivo, and whether these different posttranslational modifications—even on the same protein—indeed co-exist.

SIRT6 is involved in genomic DNA stability and repair, which plays a role in metabolism and aging. *Sirt6*^{-/-} mice die early in life,¹⁴ have reduced IGF1 levels and are severely

hypoglycemic¹⁴, possibly mediated by hypoxia-inducible factor 1 (HIF1 α)-dependent activation of glycolysis²⁰. This switch towards glycolysis causes increased glucose uptake in muscle and brown adipose tissue, explaining the fatal hypoglycemia that these mice developed²⁰. Interestingly, mice with neural-specific ablation of *Sirt6* are small at birth due to reduced growth hormone and IGF1 levels, reach normal body weight at 1 year of age, and become obese later in life, effects that are accompanied by strong hyperacetylation of histone H3K9 and H3K5663.

Finally, SIRT7 was reported to activate RNA polymerase I transcription, although its protein substrate is still unknown¹⁵. Another function for SIRT7 is derived from the study of *Sirt7*^{-/-} mice, which display cardiac hypertrophy accompanying reduced lifespan⁶⁴. The cardiac dysfunction is linked to p53 hyperacetylation⁶⁴, but further studies will have to determine if p53 is indeed deacetylated by both SIRT1 and SIRT7, and if so, whether and how these two sirtuins interconnect on this target.

Regulation of sirtuin activity

Regulation of sirtuin activity occurs at various levels. As mentioned above, subcellular localization partly determines activity. Additional regulation is required, however, as several sirtuins share the same compartment — for example, SIRT3-SIRT5 — but also to allow specification of sirtuin activity towards distinct substrates. Transcriptional regulation, post-translational modifications, protein complex formation and enzymatic substrate levels all contribute to the activity of sirtuins to different degrees, even though not much is known about the extent of which they contribute to their regulation, especially in vivo. Nutrients and small molecules can also modulate sirtuin activity, opening opportunities for therapeutic interventions. We focus primarily on the best-described sirtuin, SIRT1, but discuss the regulation of other sirtuins where appropriate.

Regulation by expression

SIRT1 expression changes in various physiological conditions, resulting in induction during low energy status, and repression during energy excess states. For instance, nutrient starvation increases⁶⁵, whereas high-fat diet reduces SIRT1 expression⁶⁶. *SIRT1* promoter analysis revealed binding sites for various transcription factors (FOXO¹⁶⁵, CREB (cAMP response element-binding) and ChREBP (carbohydrate response element-binding protein))⁶⁷ and PPAR response elements^{68,69}, which suggests that these transcription factors regulate SIRT1 expression in response to these stimuli. Indeed, FOXO¹⁶⁵, PPAR α ⁶⁸, PPAR β / δ ⁷⁰ and CREB⁶⁷ increase SIRT1 levels, whereas PPAR γ ⁶⁹ and ChREBP⁶⁷ repress SIRT1 expression (FIG. 1). In addition, HIC1 (hypermethylated in cancer 1) functions as a transcriptional repressor of SIRT1⁷¹. This repression is mediated by the transcriptional repressor CtBP (carboxyl-terminal binding protein), and is enhanced by NADH⁷² (FIG. 1), in line with repression of SIRT1 expression in times of energy excess. Finally, poly(ADP-ribose) polymerase 2 (PARP2), which belongs to a family of nuclear enzymes involved in DNA repair, apoptosis and transcription, binds and represses the *SIRT1* promoter (see below), although the exact mechanism is not yet understood⁷³ (FIG. 1). Importantly, CREB,

ChREBP67 and PARP273, not only regulate sirtuin expression *in vitro* but also have been shown to control its expression *in vivo*.

At a different level of regulation, microRNAs (miRNAs) modulate mRNA levels through the degradation of the primary transcript, or by inhibition of translation. As such, mouse miR-34a represses SIRT1 expression following genotoxic stress74. Interestingly, the miR-34a-mediated SIRT1 repression was increased in diet-induced obesity75, suggesting a physiological relevance for this interaction. miR-199a also represses SIRT1 expression (FIG. 1), as well as that of the oxygen sensor HIF1 α 76. During hypoxia, miR-199a is repressed in cardiac myocytes, allowing SIRT1 and HIF1 α expression, thereby stabilizing p53 and reducing apoptosis76.

Although not much is known about the transcriptional control of the other sirtuins, gain-of-function studies revealed that SIRT3 expression is activated by ERR α , a nuclear receptor controlling mitochondrial function, which, together with PGC1 α , binds the *Sirt3* promoter and controls the expression of genes involved in brown adipose tissue development and function77. The extent of *Sirt3* transcriptional regulation in physiological processes is not clear at present as illustrated by the fact that *Sirt3* mRNA expression increased after one week of high-fat diet but decreased after 13 weeks of diet50.

Regulation by post-translational modifications

Regulation of sirtuin activity by post-translational modifications is poorly understood. Several phosphorylation sites on SIRT1 have been identified78. SIRT1 is phosphorylated *in vitro* by cyclinB–Cdk1, which binds SIRT1, and mutation of the phosphorylation sites disturbs normal cell cycle progression78 (FIG. 1). The cJUN N-terminal kinase (JNK) also phosphorylates SIRT1 at three residues, particularly during oxidative stress79, and this results in deacetylation of histone H3, but not of p5379, suggesting that phosphorylation directs SIRT1 to specific targets (FIG. 1). In addition, the dual specificity tyrosine-phosphorylated and regulated kinases DYRK1 and DYRK3 phosphorylate SIRT1 at the Thr⁵²² residue80. This activating phosphorylation leads to enhanced SIRT1-mediated p53 deacetylation and prevents apoptosis within the context of genotoxic stress80 (FIG. 1).

SIRT1 has also been shown to be sumoylated, which in cultured cells increases its activity81. Following genotoxic stress, for instance ultraviolet light or hydrogen peroxide, the desumoylase SENP removes this modification, inactivating SIRT1 and promoting cell death81 (FIG. 1). It is tempting to speculate that such conditions also activate the PARP enzymes — which constitute a family of major NAD⁺ consumers — and thereby deplete NAD⁺ levels, also inhibiting SIRT1 activity82. Whether these two events occur simultaneously would be interesting to explore.

Regulation by complex formation

Sirtuins are further regulated by forming complexes with other proteins. AROS (active regulator of SIRT1) is the only protein known to positively regulate SIRT1 following complex formation, thereby suppressing p5383.

By contrast, several negative regulators have been described. NCoR1 (nuclear receptor co-repressor 1) and SMRT (silencing mediator of retinoid and thyroid hormone receptors), form a complex with SIRT1 and PPAR γ during fasting to repress the PPAR γ -mediated induction of adipogenesis⁸⁴.

DBC1 (deleted in breast cancer) binds the SIRT1 catalytic domain and inhibits its activity *in vitro* during genotoxic stress^{85,86}. The physiological relevance of the DBC1-SIRT1 complex was confirmed, as complex formation was inhibited during fasting but increased in mice kept on a high-fat diet⁸⁷. Consistent with this, deletion of *Dbc1* resulted in protection against high-fat diet-induced liver steatosis, even though these mice were — surprisingly — slightly heavier than control littermates⁸⁷.

The histone methyltransferase LSD1 (lysine-specific demethylase 1) also interacts with the SIRT1 catalytic domain to regulate the expression of downstream Notch target genes⁸⁸. SIRT1-mediated deacetylation of both H4K16 and H1K26, in conjunction with LSD1-mediated demethylation of H3K4, results in convergent repression of Notch target genes⁸⁸. As such, the abnormal wing development of *Drosophila melanogaster* Notch mutants can be rescued by deletion of either the flies orthologues *Sir2* or *Lsd1*⁸⁸.

Regulation through NAD⁺

As mentioned above, sirtuins depend on the cofactor NAD⁺ for their activity, and therefore the availability of NAD⁺ is another point of regulation.

NAD⁺ levels are modulated in several ways. For instance, a regulation of relative NAD⁺ levels lies in the conversion to its reduced form NADH, for instance in glycolysis, thereby limiting the availability of NAD⁺ to serve as a sirtuin substrate³⁹. During fasting and exercise muscle NAD⁺ levels rise, with a concomitant activation of sirtuins³⁸. Similarly, caloric restriction increases NAD⁺ levels in muscle, liver and white adipose tissue (WAT)⁸⁹. By contrast, high-fat diet in mice reduces NAD⁺/NADH ratio⁹⁰.

NAD⁺ can be synthesized from various precursors. De novo biosynthesis starts from the amino acid tryptophan and occurs primarily in the liver and kidney (reviewed in 24). However, NAD⁺ can also be synthesized from nicotinic acid (known as the Preiss-Handler pathway) or nicotinamide (through the salvage pathway), both of which are present in our diet as vitamin B3⁹¹ (FIG. 1). Interestingly, nicotinamide riboside, which is found in milk and already known to boost NAD⁺ synthesis in bacteria, was recently demonstrated to act as a NAD⁺ precursor and to enhance NAD⁺ synthesis through the salvage pathway in eukaryotic cells⁹². Additionally, treatment of mice with another NAD⁺ precursor — nicotinamide mononucleotide — activates SIRT1 and improves glucose tolerance in mice⁹³, although it should be noted that this precursor does not occur in our diet. Future studies will have to determine whether the naturally occurring nicotinic acid, nicotinamide and/or nicotinamide riboside can activate sirtuins *in vivo*, and clarify the physiological importance of these precursors.

In addition to biosynthesis, manipulating the activities of NAD⁺-depleting enzymes would also alter NAD⁺ levels, thereby regulating sirtuin activity. PARPs are considered the major

NAD⁺ degrading enzymes^{94,95}. When activated by DNA damage they catalyze the transfer of ADP-ribose units from NAD⁺ to substrate proteins to form branched polymers of ADP-ribose, leading to the decline of intracellular NAD⁺ levels²⁴.

As SIRT1 and PARPs compete for the same intracellular NAD⁺ pool, a functional link between PARPs and SIRT1 has been proposed. Indeed, two recent reports revealed that the deletion of *Parp1* and *Parp2* in mice activates SIRT1, leading to increased numbers of mitochondria, enhanced energy expenditure and protection from diet-induced obesity^{73,82}. *Parp1* and *Parp2* deletions activate SIRT1 via two distinct mechanisms: deletion of *Parp1* boosts the intracellular NAD⁺ levels; and deletion of *Parp2*, which is a repressor of *SIRT1* expression (see above), increases *SIRT1* expression. Treatment of cells or mice with the pan-PARP inhibitor PJ34 results also in SIRT1 activation similar to that observed after *Parp* deletion⁸². Consistent with nuclear localization of both SIRT1 and PARPs, *Parp1* deletion does not increase the deacetylation activity of cytosolic SIRT2 or mitochondrial SIRT3^{73,82}, suggesting that the increase in NAD⁺ is confined to the nuclear compartment

Similarly to PARP depletion, deletion of cADP-ribose synthase 38 (CD38), another important NAD⁺ consumer, also increases NAD⁺ levels, SIRT1 activity and mimics the metabolic phenotype expected for SIRT1 activation⁹⁶. Interestingly, specific CD38 inhibitors have also been developed⁹⁷, which together with PARP inhibitors, open new avenues for pharmacological sirtuin activation (FIG. 1). It will be important to determine whether these strategies are specific for SIRT1, or whether more sirtuins will be affected.

Compounds regulating sirtuin activity

Natural compounds that activate SIRT1 have been identified, providing further insights into sirtuin regulation (reviewed in 98). A small molecule screen in yeast revealed that several plant polyphenols — notably resveratrol — can induce SIRT1 to deacetylate p53-based peptides *in vitro* and treatment of *S. cerevisiae* with these compounds increased lifespan⁹, although some doubt surrounds these results (Box 2). Resveratrol also increases SIRT1 activity and enhances mitochondrial function in mice^{41,42}, protecting them against diet-induced obesity and improving exercise performance and cold-resistance⁴¹. When fed a high-fat diet, resveratrol-treated mice also live longer^{42,99}. Resveratrol improves mitochondrial activity and metabolic control in humans as well¹⁰⁰. Interestingly, in humans significant lower resveratrol doses (~200-fold) resulted in similar plasma resveratrol levels, AMPK activation and comparable physiological effects compared to mice¹⁰⁰. Several synthetic compounds have also been described that can activate the SIRT1 pathway. The most potent of these is SRT1720¹⁰¹, which, similarly to resveratrol, protects against diet-induced obesity by improving mitochondrial function⁴⁰ and extends the lifespan of obese mice³⁷.

Even though the physiological effects of resveratrol and SRT1720 are widely accepted, the mechanism by which they activate SIRT1 is unclear. Originally, these compounds were thought to directly activate SIRT1 by changing its enzymatic properties — lowering its K_m for both the protein substrate and NAD⁺^{9,101} — but more recent reports contest these results^{38,39,102–105}. Instead of activating SIRT1, resveratrol was shown to activate AMPK^{40,42}, possibly through inhibition of oxidative phosphorylation¹⁰⁶ Arguing in favor

of the importance of AMPK is that the resveratrol effect was lost in AMPK-deficient mice^{38,104}, even though one could argue that this does not demonstrate directionality of the AMPK-SIRT1 interaction. In these same mice, however, the NAD⁺/NADH ratio increased by resveratrol in an AMPK-dependent manner, allowing downstream activation of sirtuins¹⁰⁴ (FIG. 1). Similarly, established AMPK agonists, such as AICAR, increase NAD⁺ levels and activate SIRT1-dependent PGC1 α deacetylation³⁹, and time-course experiments revealed that AMPK activation by exercise or fasting precedes a rise in NAD⁺ levels and SIRT1 activation³⁸.

Sirtuins in glucose metabolism

The maintenance of relatively constant blood glucose concentrations is essential to provide energy to tissues, most importantly for an uninterrupted glucose supply to the brain, which almost exclusively uses glucose as an energy source. Glucose levels are regulated through various processes, including intestinal glucose uptake, hepatic glucose output, and glucose uptake, utilization and storage in peripheral tissues. The main regulating hormone — insulin — promotes glucose uptake in peripheral tissues (muscle and WAT), glycolysis and storage of glucose as glycogen in the fed state. Glucagon counteracts the effect of insulin and stimulates hepatic glucose production during fasting. Sirtuins modulate a range of cellular processes involved in maintaining glucose homeostasis in tissues such as muscle, WAT, liver and pancreas (FIG. 4).

Gluconeogenesis and insulin sensitivity

Gluconeogenesis is a cytosolic process that increases glucose production, mainly from the liver, in situations when the supply of energy is limiting such as during fasting, calorie restriction and exercise¹⁰⁷. Intriguingly, SIRT1 has a dual and controversial role in the control of gluconeogenesis. On the one hand, SIRT1 can suppress hepatic glucose production by deacetylating the transcription factor CRTC2 (CREB-regulated transcription coactivator 2), leading to CRTC2 degradation and consequent reduction in the transcription of gluconeogenic genes (FIG. 2 and 4)¹⁰⁸. On the other hand, SIRT1 can also stimulate the gluconeogenic transcriptional program by deacetylating and activating FOXO1^{108,109} and PGC1 α ³⁶ (FIG. 2 and 4). However, it should be noted that genetically increased PGC1 α expression clearly enhances gluconeogenesis but the evidence supporting the relevance of physiological modulation of PGC1 α in the control of gluconeogenesis is weak¹¹⁰. Given that the exact contribution of the activities of CRTC2, FOXO1 and PGC1 α to gluconeogenesis is still under debate, it is unclear which of these above-mentioned SIRT1 actions is the primary and/or predominant event. Furthermore, recent studies revealing that a temporal regulation of SIRT1 expression and deacetylation of SIRT1's targets such as CRTC2 is central to the control of the appropriate rate of gluconeogenesis^{67,108} have made this story even more intricate.

In contrast to SIRT1, SIRT2-4 are thought to maintain gluconeogenesis, in particular during times of energy limitation. Specifically, SIRT2 deacetylates and increases the stability of the gluconeogenic enzyme PEPCK upon glucose deprivation⁶⁰ (FIG. 2). Furthermore, SIRT3 and SIRT4 may regulate gluconeogenesis from amino acids during caloric restriction via

their target GDH, a mitochondrial enzyme converting glutamate to α -ketoglutarate, facilitating glucose production via TCA cycle 17,48,57 (FIG. 2 and 4). To fully understand the role of these sirtuins in the regulation of gluconeogenesis, further studies are clearly needed.

Despite the conflicting findings in gluconeogenesis, it is tempting to propose that SIRT1 may function as an insulin sensitizer on the basis of the metabolic changes (lowered fasting glucose levels and/or hepatic glucose production) observed in SIRT1 transgenic mice¹¹¹, after adenovirus-mediated SIRT1 overexpression¹⁰⁸, in SIRT1 activator-treated mice^{40,42,101}, and in resveratrol-treated obese humans¹⁰⁰. Moreover, SIRT1 activation also protects from diet-induced and genetic insulin resistance in mice^{42,100,101}, and *SIRT1* mRNA expression in adipose tissue positively correlates with insulin sensitivity in humans during hyperinsulinaemia¹¹². Mice lacking SIRT1 specifically in the liver have been shown to develop insulin resistance¹¹³ or maintain normal glucose homeostasis^{89,114}, whereas acute adenoviral liver SIRT1 knockdown induces fasting hypoglycaemia¹¹⁵. This suggests that the effect of acute SIRT1 liver knockdown on glucose metabolism may be compensated in situations of chronic SIRT1 deficiency. Furthermore, SIRT3 also plays a role in insulin sensitization as its absence may contribute to development of insulin resistance in the muscle via increasing ROS production and impairing mitochondrial oxidation⁵⁵. Based on these studies, the pharmacological targeting of SIRT1 is a promising treatment for type 2 diabetes.

Glycolysis

Glycolysis is the main pathway for glucose utilization in the fed state, in which glucose is catabolized into pyruvate in the cytosol¹⁰⁷. Under anaerobic conditions (e.g. in exercising muscle), pyruvate is converted by lactate dehydrogenase into lactate. In aerobic conditions, energy from glucose is released through glucose oxidation, a process in which pyruvate and the reducing equivalents produced during glycolysis fuel mitochondrial oxidative phosphorylation to generate ATP.

Recent studies have provided insights into the role of different sirtuins in glycolysis. It is now well established that SIRT1 is involved in the control of glycolysis by activating PGC1 α , which attenuates the transcription of glycolytic genes³⁶ (FIG. 2 and 4). Furthermore, SIRT1, SIRT3 and SIRT6 all suppress the transcription factor HIF1 α , which represses glucose oxidation through TCA cycle¹¹⁶. SIRT1 suppresses HIF1 α directly through deacetylation¹¹⁷ (FIG. 2 and 4), whereas SIRT3 inhibits the ROS-mediated stabilization of HIF1 α by activating SOD2¹¹⁸ and possibly increasing reduced glutathione levels⁵² and thereby enhancing cellular antioxidant defenses (FIG. 2 and 4). SIRT6 acts as a corepressor of HIF1 α to diminish glycolysis during the normal nutritional state²⁰ (FIG. 2 and 4).

When integrating these observations, SIRT1, SIRT3 and SIRT6 act to inhibit glycolysis and stimulate mitochondrial oxidation of fatty acids. This finding is particularly interesting, as tumor cells have a high reliance on glycolysis, known as the Warburg effect. Therefore, this switch from glycolysis to oxidative metabolism induced by sirtuin activators^{117,118} and PARP inhibitors⁸², which indirectly activate SIRT1, could contribute to their anti-tumor activity.

Insulin secretion

The secretion of the hormone insulin from pancreatic β -cells is tightly coupled to blood glucose levels, via an intricate signalling pathway¹¹⁹. After entering the β -cell via glucose transporter 2, glucose is metabolized to generate ATP through glucose oxidation. The subsequent increase in ATP/ADP ratio closes ATP-sensitive potassium channels, leading to β -cell depolarization and calcium influx, ultimately coupling insulin release to plasma glucose levels. Although glucose is the most potent stimulator of insulin secretion it is also induced by some amino acids.

SIRT1 has been shown to induce glucose-stimulated insulin secretion by increasing the yield of ATP produced from glucose oxidation. This is achieved through transcriptional repression of the uncoupling protein 2 (UCP2) (FIG. 2 and 4), which uncouples mitochondrial ATP production during oxidative phosphorylation. As such, SIRT1 deficiency results in high UCP2 levels and diminished insulin secretion^{120,121}.

As discussed above, both SIRT3 and SIRT4 target GDH (FIG. 2 and 4), although in opposite fashion, and thereby impact on amino-acid induced insulin secretion during calorie restriction as GDH catalyzes formation of α -ketoglutarate, which can be used for ATP production via the TCA cycle and oxidative phosphorylation. Specifically, SIRT4 seems to inhibit insulin secretion, as SIRT4 deficiency increases GDH activity in pancreatic islet cells and increases amino acid-stimulated insulin secretion¹⁷. Furthermore, SIRT4 overexpression in insulinoma cells leads to blunted insulin secretion¹²². Although SIRT3 has been proposed to activate GDH^{48,57}, GDH activity is unchanged in *Sirt3*^{-/-} mice²¹, so the physiological role of SIRT3 in GDH regulation and insulin secretion is unclear.

SIRT1 and SIRT4 therefore seem to control insulin secretion in opposing directions in response to feeding and calorie restriction. Although the elucidation of underlying mechanisms is under way, the current findings suggest the existence of a sirtuin network to maintain proper insulin secretion.

Sirtuins in lipid metabolism

Lipid metabolism comprises lipid synthesis, uptake, storage and utilization, which requires tight control, for example during periods of fasting or prolonged exercise. Insulin promotes hepatic triglyceride synthesis and storage of triglycerides in WAT upon feeding, whereas glucagon and epinephrin stimulates lipolysis in the WAT and fatty acid oxidation in other tissues when nutrients are limiting. Sirtuins influence diverse aspects of lipid homeostasis in multiple tissues; here we concentrate on their effects in WAT, liver and skeletal muscle (FIG. 4). We do not discuss the role of sirtuins in cholesterol and bile acid metabolism (for a review, see ¹²³).

Lipid synthesis

When whole body energy stores are maximal, excess glucose, fatty acids and amino acids are used in the liver to synthesize fatty acids, which are exported to WAT where they are stored as triacylglycerols¹²⁴. Fatty acid synthesis occurs in cytosol where acetyl-CoA, derived from fuel catabolism, and malonyl-CoA are used as substrates for fatty acids

production, catalyzed by fatty acid synthase. A key transcription factor controlling the expression of genes involved in lipid synthesis is liver X receptor (LXR), which in part mediates its effect through the induction of the sterol-response element-binding protein 1c (SREBP1c)¹²⁵. SIRT1 deacetylates and subsequently increases the transcriptional activity of LXR¹²⁶. Therefore, SIRT1 activation could theoretically increase fatty acid synthesis. However, SIRT1 also deacetylates the downstream target of LXR, SREBP1c, thereby destabilizing it and reducing its occupancy on the lipogenic gene promoters leading to suppression of fatty acid synthesis (FIG. 3 and 4)^{127,128}. This notion is supported by the fact that *Sirt1* transgenic mice are protected from hepatic steatosis¹²⁹ and *Sirt1*^{-/-} mice are prone to develop hepatic steatosis^{114,130} (see Lipid utilization and energy expenditure section). Therefore, SIRT1-mediated LXR activation seems to target cholesterol metabolism (for a review, see 123) rather than triglyceride synthesis.

SIRT6 has also been implicated in the control of fatty acid synthesis (FIG. 3). Indeed, genes involved in fatty acid transport and lipogenesis are induced in liver-specific *Sirt6*^{-/-} mice¹³¹, suggesting that SIRT6 serves as a negative regulator of triglyceride synthesis.

Lipid storage

Fatty acids can be stored as cytosolic triacylglycerols droplets in all cells, but the prime storage occurs in adipocytes of WAT¹³². The development of adipocytes from preadipocytes — adipogenesis — is controlled by a complex transcriptional program coordinated mainly by the nuclear receptor PPAR γ , the master regulator of adipocyte differentiation¹³³.

In differentiated adipocyte cell lines, SIRT1 inhibits adipogenesis and enhances fat mobilization through lipolysis⁸⁴ by suppressing the activity of PPAR γ . SIRT1 achieves this by promoting the assembly of a corepressor complex, involving NCoR1 and SMRT, on the promoters of PPAR γ target genes to repress their transcription (FIG. 3 and 4) and limit fat storage in situations of caloric restriction and fasting⁸⁴. Cell-based studies have suggested that SIRT2 may also inhibit adipogenesis and promote lipolysis during nutrient deprivation, by deacetylating and activating FOXO1 (FIG. 3), promoting the binding of FOXO1 to PPAR γ and repressing its transcriptional activity^{61,134}. However, further research is required to establish the existence of a mechanistic link between SIRT1 and SIRT2 with PPAR γ and FOXO1 in vivo.

Lipid utilization and energy expenditure

Fatty acid oxidation occurs mainly in the mitochondrial matrix. Therefore, long-chain fatty acids need first to be transported from the cytoplasm into mitochondria¹³⁵, where they undergo β -oxidation to generate acetyl-CoAs, which can be used for ATP production via TCA cycle and oxidative phosphorylation. As malonyl-CoA, an intermediate of fatty acid synthesis, inhibits carnitine palmitoyltransferase, the enzyme controlling the mitochondrial import of fatty acids, low levels of malonyl-CoA facilitate oxidation of fatty acids.

Fatty acid oxidation is a major determinant of whole body energy expenditure as it consumes high amounts of oxygen. SIRT1 enhances energy expenditure by stimulating fatty acid oxidation, as well as oxidative phosphorylation, in response to fasting. This is achieved through activating PPAR α and its coactivator PGC1 α ¹¹⁴ that stimulate expression of genes

involved in fatty acid uptake and/or β -oxidation (FIG. 3 and 4). In support of this notion, SIRT1 activation protects mice from diet-induced obesity by increasing the rate of fatty acid oxidation^{40,41}. Furthermore, in humans, *SIRT1* mRNA expression positively correlates with energy expenditure during hyperinsulinaemic clamp¹¹², the gold standard to measure insulin sensitivity, and three *Sirt1* single-nucleotide polymorphisms are associated with whole body energy expenditure in Finnish subjects⁴¹, confirming the important and conserved role of SIRT1 in the modulation of whole body energy expenditure.

Fatty acids are an important source of energy in the liver during fasting, CR and high-fat feeding. SIRT1 has been shown to be an important regulator of fatty acid oxidation in the liver. Indeed, induction of fatty acid oxidation through activation of PPAR α and PGC1 α and their target genes is impaired during fasting in mice lacking SIRT1 specifically in the liver^{114,115}. As reduced fatty acid oxidation correlates with hepatic steatosis, liver-specific and heterozygous germline *Sirt1*^{-/-} mice are susceptible to hepatic steatosis under standard and high-fat diets^{114,130,136}. Surprisingly, one strain of liver-specific *Sirt1*^{-/-} mice is protected from hepatic steatosis and diet-induced obesity⁸⁹. Despite this, most findings support that SIRT1 stimulates lipid utilization. For example adenoviral overexpression of SIRT1¹³⁷, *Sirt1* transgenic mice¹²⁹, and pharmacological SIRT1 activation^{40,127,128,138,139} improve liver steatosis in diet-induced and genetically obese mouse models. In addition, resveratrol treatment reduces hepatic fat content in obese humans¹⁰⁰.

Of the other sirtuins, SIRT3, SIRT4 and SIRT6 are also involved in the regulation of fatty acid oxidation in the liver. As discussed above, SIRT3 deacetylates and activates LCAD⁴⁹ (FIG. 2 and 3), a key enzyme involved in the oxidation of long-chain fatty acids. By contrast, SIRT4 seems to be a negative regulator of fatty acid oxidation⁶² (FIG. 3), whereas SIRT6 was reported to stimulate expression of genes involved in fatty acid oxidation as well as fatty acid oxidation¹³¹, although the exact mechanism is unclear. Importantly, both SIRT3-deficient mice and liver-specific *Sirt6*^{-/-} mice are more susceptible to hepatic steatosis^{49,131}. Altogether, SIRT1, SIRT3 and SIRT6 may be potential therapeutic targets to treat liver diseases characterized by lipid accumulation.

Skeletal muscle uses fatty acids as a fuel during fasting, prolonged exercise and high-fat feeding. The switch to oxidative metabolism includes the induction of mitochondrial biogenesis, fatty acid oxidation and oxidative phosphorylation, processes that are controlled by the yin and yang between corepressors such as NCoR1¹⁴⁰ and coactivators, such as PGC1 α ^{141,142}, which determine the transcriptional activity of downstream targets controlling oxidative metabolism. However, what are the key events leading to the shift towards more oxidative metabolism in skeletal muscle? AMPK is a cellular energy sensor that is activated during exercise or energy demand by an increase in the AMP/ATP ratio² (FIG. 4). Activated AMPK phosphorylates PGC1 α directly¹⁴³ and also stimulates SIRT1 indirectly by boosting cellular NAD⁺ levels³⁹ (FIG. 4). Nevertheless, the activation of SIRT1 may be AMPK-independent in skeletal muscle during calorie restriction^{144,145} but this is not a consistent finding¹⁴⁶. Once SIRT1 is activated by NAD⁺, it deacetylates and locks PGC1 α in an active state³⁶, which together with reduced activity of NCoR1¹⁴⁰ will favor oxidative metabolism (FIG. 4). Recent data have implied that the nuclear abundance of

the key PGC1 α acetyltransferase, GCN5 (general control of amino-acid synthesis 5)35 also diminished in response to exercise, which could also contribute to the decreased PGC1 α acetylation147. However, further work is needed to determine the function and regulation of coactivators, such as GCN535 and corepressors, such as NCoR1 in the control of oxidative metabolism. In addition to the role of SIRT1, SIRT3-dependent deacetylation and activation of LCAD49 and oxidative phosphorylation complexes53–55, as discussed above, might affect fatty acid oxidation in skeletal muscle.

Interestingly, in states of energy excess, for instance following high-fat feeding, these processes typifying situations of high energy demand, are reversed. As such, the cellular AMPK and SIRT1 activities are attenuated due to high intracellular ATP and low NAD⁺ levels148 (FIG. 4). Furthermore, high-fat feeding induces the expression of GCN5 while concomitantly reducing SIRT1 levels, resulting in the inhibition of PGC1 α by increasing its acetylation level66 (FIG. 4). Lastly, during energy excess NCoR1 is activated leading to decreased transcription of genes governing mitochondrial activity140.

Conclusions and future perspectives

Sirtuins constitute a protein family of metabolic sensors, translating changes in NAD⁺ levels into adaptive responses. Although the relevance of SIRT1 as a *strictu sensu* longevity gene has been disputed (Box 2), it is evident that by regulating the activity of its target enzymes and transcription factors, sirtuins affect health in a pleiotropic manner. The fact that sirtuin activation prevents diet-induced obesity, and their overexpression prevents cancer risk, suggests that sirtuins are more involved in stress responses. This implies that while unstressed by for instance genotoxic or metabolic (high fat diet) stress, or ageing, activation or ectopic expression of sirtuins does not impact physiological fitness. On the other hand, following such external stressors, enhanced sirtuin activity serves to activate protective pathways, and can thereby impact lifespan. As such, they should still be considered as candidate targets for the prevention and/or treatment of age-related diseases and to increase healthspan. In fact, in contrast to increasing lifespan, which has limited medical relevance, improving healthspan has an immediate clinical and public health impact, given the ever increasing ‘greying’ of the world population.

Besides the relevance of sirtuin activators within the context of common diseases of ageing, it would be worth testing sirtuin activators for the treatment of more rare, but also more insidious, inherited diseases relating to mitochondrial metabolism. This was recently exemplified by treating fibroblasts of patients with a mitochondrial fatty acid oxidation disorder with resveratrol, which resulted in restoration of fatty acid degradation158. Altogether, although sirtuins might have lost their immaculate Methuselah image, they are still likely to help those in need for a metabolic Samaritan.

Acknowledgements

We apologize to colleagues whose original work we have been unable to cite owing to space limitations. We thank team members of the Auwerx lab for discussions. RHH is supported by a Rubicon fellowship of the Netherlands Organization for Scientific Research (NWO), and EP is funded by the Academy of Finland and the Finnish Cultural Foundation. JA is the Nestlé Chair in Energy Metabolism. The work in the Auwerx laboratory is supported by grants of the Ecole Polytechnique Fédérale de Lausanne, Faculty of Life Science, the EU Ideas program

(ERC-2008-AdG-23118), the Velux Stiftung, the Swiss National Science Foundation (31003A-124713 and 31003A-125487).

Glossary terms

caloric restriction

A reduction of caloric intake (typically 20-50% less than average) that was shown to increase lifespan in a variety of organisms

ADP-ribosyltransferases

Enzymes that transfer an ADP-ribose group on a protein target

Demalonylase

Enzyme that removes a malonyl group from a specific lysine residue of a target protein.

Desuccinylate

Enzyme that removes a succinyl group from a specific lysine residue of a target protein.

Ketone body

Metabolic energy unit, derived from fat breakdown, which serves especially to fuel the brain in times of low blood glucose concentrations.

TCA cycle

Also known as Krebs cycle. Acetyl-CoA derived from glucose or fat breakdown is further metabolized to offer reduced energy equivalents that are used by mitochondrial oxidative phosphorylation to generate ATP.

Reactive oxygen species

Oxygen radicals that are produced by the mitochondrial respiratory chain. In excess, they can cause intracellular and mitochondrial damage, which promotes cell death.

K_m

Michaelis constant. Enzyme property describing the enzyme's substrate concentration at which the enzyme works at half-maximal capacity.

Oxidative phosphorylation

Mitochondrial enzymatic chain of events by which ATP is generated

Hyperinsulinaemia

A condition that occurs when there is excess of insulin in the circulation.

Fasting hypoglycaemia

A condition during fasting that occurs when circulating glucose levels are abnormally low.

Insulinoma cells

Tumor cells derived from pancreatic beta-cells which secrete insulin

Single-nucleotide polymorphisms

A naturally occurring single nucleotide variation in a DNA sequence. The most common type of genetic polymorphism

Steatosis

A condition characterized by abnormal accumulation of lipid within the cell.

References

- Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. *Nat Rev Mol Cell Biol.* 2011; 12:21–35. [PubMed: 21157483]
- Canto C, Auwerx J. AMP-activated protein kinase and its downstream transcriptional pathways. *Cell Mol Life Sci.* 2010; 67:3407–3423. [PubMed: 20640476]
- Houtkooper RH, Williams RW, Auwerx J. Metabolic networks of longevity. *Cell.* 2010; 142:9–14. [PubMed: 20603007]
- Fontana L, Partridge L, Longo VD. Extending healthy life span--from yeast to humans. *Science.* 2010; 328:321–326. [PubMed: 20395504]
- Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. *Annu Rev Pathol.* 2010; 5:253–295. [PubMed: 20078221]
- Guarente L, Franklin H. Epstein Lecture: Sirtuins, aging, and medicine. *N Engl J Med.* 2011; 364:2235–2244. [PubMed: 21651395]
- Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in *Saccharomyces cerevisiae* by two different mechanisms. *Genes Dev.* 1999; 13:2570–2580. [PubMed: 10521401]
- Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. *Nature.* 2000; 403:795–800. [PubMed: 10693811] **[This study describes the NAD dependence of the yeast Sir2 protein]**
- Howitz KT, et al. Small molecule activators of sirtuins extend *Saccharomyces cerevisiae* lifespan. *Nature.* 2003; 425:191–196. [PubMed: 12939617] **[This report describes the first small molecule screen for sirtuin activators, identifying resveratrol as a calorie restriction mimetic]**
- Frye RA. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. *Biochem Biophys Res Commun.* 2000; 273:793–798. [PubMed: 10873683]
- Tanno M, Sakamoto J, Miura T, Shimamoto K, Horio Y. Nucleocytoplasmic shuttling of the NAD +-dependent histone deacetylase SIRT1. *J Biol Chem.* 2007; 282:6823–6832. [PubMed: 17197703]
- Vaquero A, et al. SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. *Genes Dev.* 2006; 20:1256–1261. [PubMed: 16648462]
- Huang JY, Hirschey MD, Shimazu T, Ho L, Verdin E. Mitochondrial sirtuins. *Biochim Biophys Acta.* 2010; 1804:1645–1651. [PubMed: 20060508]
- Mostoslavsky R, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. *Cell.* 2006; 124:315–329. [PubMed: 16439206]
- Ford E, et al. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. *Genes Dev.* 2006; 20:1075–1080. [PubMed: 16618798]
- Braunstein M, Sobel RE, Allis CD, Turner BM, Broach JR. Efficient transcriptional silencing in *Saccharomyces cerevisiae* requires a heterochromatin histone acetylation pattern. *Mol Cell Biol.* 1996; 16:4349–4356. [PubMed: 8754835]
- Haigis MC, et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. *Cell.* 2006; 126:941–954. [PubMed: 16959573]
- Liszt G, Ford E, Kurtev M, Guarente L. Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase. *J Biol Chem.* 2005; 280:21313–21320. [PubMed: 15795229]
- Michishita E, et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. *Nature.* 2008; 452:492–496. [PubMed: 18337721]
- Zhong L, et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. *Cell.* 2010; 140:280–293. [PubMed: 20141841]

21. Nakagawa T, Lomb DJ, Haigis MC, Guarente L. SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. *Cell*. 2009; 137:560–570. [PubMed: 19410549]
22. Peng C, et al. The first identification of lysine malonylation substrates and its regulatory enzyme. *Mol Cell Proteomics*. 2011
23. Du J, et al. Sirt5 Is an NAD-Dependent Protein Lysine Demalonylase and Desuccinylase. *Science*. 2011; 334:806–809. [PubMed: 22076378] [**References 22 and 23 describe desuccinylation and demalonylation as a novel function for SIRT5. Reference 23 identifies CPS1 as a desuccinylated target.**]
24. Houtkooper RH, Canto C, Wanders RJ, Auwerx J. The secret life of NAD⁺: an old metabolite controlling new metabolic signaling pathways. *Endocr Rev*. 2010; 31:194–223. [PubMed: 20007326]
25. Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, Sinclair DA. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. *J Biol Chem*. 2002; 277:45099–45107. [PubMed: 12297502]
26. Anderson RM, Bitterman KJ, Wood JG, Medvedik O, Sinclair DA. Nicotinamide and PNC1 govern lifespan extension by calorie restriction in *Saccharomyces cerevisiae*. *Nature*. 2003; 423:181–185. [PubMed: 12736687]
27. Kustatscher G, Hothorn M, Pugieux C, Scheffzek K, Ladurner AG. Splicing regulates NAD metabolite binding to histone macroH2A. *Nat Struct Mol Biol*. 2005; 12:624–625. [PubMed: 15965484]
28. Liou GG, Tanny JC, Kruger RG, Walz T, Moazed D. Assembly of the SIR complex and its regulation by O-acetyl-ADP-ribose, a product of NAD-dependent histone deacetylation. *Cell*. 2005; 121:515–527. [PubMed: 15907466]
29. Tong L, Denu JM. Function and metabolism of sirtuin metabolite O-acetyl-ADP-ribose. *Biochim Biophys Acta*. 2010; 1804:1617–1625. [PubMed: 20176146]
30. Feige JN, Auwerx J. Transcriptional targets of sirtuins in the coordination of mammalian physiology. *Curr Opin Cell Biol*. 2008; 20:303–309. [PubMed: 18468877]
31. Canto C, Auwerx J. Targeting Sirtuin 1 to Improve Metabolism: All You Need Is NAD⁺? *Pharmacol Rev*. 2011
32. Vaziri H, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. *Cell*. 2001; 107:149–159. [PubMed: 11672523]
33. Luo J, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. *Cell*. 2001; 107:137–148. [PubMed: 11672522]
34. Herranz D, Serrano M. SIRT1: recent lessons from mouse models. *Nat Rev Cancer*. 2010; 10:819–823. [PubMed: 21102633]
35. Lerin C, et al. GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1alpha. *Cell Metab*. 2006; 3:429–438. [PubMed: 16753578]
36. Rodgers JT, et al. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. *Nature*. 2005; 434:113–118. [PubMed: 15744310] [**This article provides the mechanistic link between SIRT1 activity and PGC-1α acetylation.**]
37. Minor RK, et al. SIRT1720 improves survival and healthspan of obese mice. *Sci Rep*. 2011; 1
38. Canto C, et al. Interdependence of AMPK and SIRT1 for Metabolic Adaptation to Fasting and Exercise in Skeletal Muscle. *Cell Metab*. 2010; 11:213–219. [PubMed: 20197054]
39. Canto C, et al. AMPK regulates energy expenditure by modulating NAD⁺ metabolism and SIRT1 activity. *Nature*. 2009; 458:1056–1060. [PubMed: 19262508] [**This paper describes how NAD⁺ levels link AMPK and SIRT1 activity.**]
40. Feige JN, et al. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. *Cell Metab*. 2008; 8:347–358. [PubMed: 19046567]
41. Lagouge M, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. *Cell*. 2006; 127:1109–1122. [PubMed: 17112576]
42. Baur JA, et al. Resveratrol improves health and survival of mice on a high-calorie diet. *Nature*. 2006; 444:337–342. [PubMed: 17086191] [**Reference 41 and 42 describe the beneficial effects of resveratrol treatment in mice, showing improved metabolic profile.**]

43. Brunet A, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. *Science*. 2004; 303:2011–2015. [PubMed: 14976264]
44. Motta MC, et al. Mammalian SIRT1 represses forkhead transcription factors. *Cell*. 2004; 116:551–563. [PubMed: 14980222]
45. van der Horst A, et al. FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). *J Biol Chem*. 2004; 279:28873–28879. [PubMed: 15126506]
46. Zhong L, Mostoslavsky R. Fine tuning our cellular factories: sirtuins in mitochondrial biology. *Cell Metab*. 2011; 13:621–626. [PubMed: 21641544]
47. Verdin E, Hirschev MD, Finley LW, Haigis MC. Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. *Trends Biochem Sci*. 2010; 35:669–675. [PubMed: 20863707]
48. Lombard DB, et al. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. *Mol Cell Biol*. 2007; 27:8807–8814. [PubMed: 17923681]
49. Hirschev MD, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. *Nature*. 2010; 464:121–125. [PubMed: 20203611] **[This study describes the fatty acid oxidation enzyme LCAD as a SIRT3 target and its role during fasting.]**
50. Hirschev MD, et al. SIRT3 Deficiency and Mitochondrial Protein Hyperacetylation Accelerate the Development of the Metabolic Syndrome. *Mol Cell*. 2011
51. Shimazu T, et al. SIRT3 deacetylates mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase 2 and regulates ketone body production. *Cell Metab*. 2010; 12:654–661. [PubMed: 21109197]
52. Someya S, et al. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. *Cell*. 2010; 143:802–812. [PubMed: 21094524] **[This article shows how SIRT3 regulates IDH2 activity and oxidative stress defense, and thereby mediates the effects of caloric restriction on age-related hearing loss.]**
53. Ahn BH, et al. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. *Proc Natl Acad Sci USA*. 2008; 105:14447–14452. [PubMed: 18794531]
54. Finley LW, et al. Succinate dehydrogenase is a direct target of sirtuin 3 deacetylase activity. *PLoS ONE*. 2011; 6:e23295. [PubMed: 21858060]
55. Jing E, et al. Sirtuin-3 (Sirt3) regulates skeletal muscle metabolism and insulin signaling via altered mitochondrial oxidation and reactive oxygen species production. *Proc Natl Acad Sci USA*. 2011; 108:14608–14613. [PubMed: 21873205]
56. Qiu X, Brown K, Hirschev MD, Verdin E, Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. *Cell Metab*. 2010; 12:662–667. [PubMed: 21109198]
57. Schlicker C, et al. Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5. *J Mol Biol*. 2008; 382:790–801. [PubMed: 18680753]
58. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The human Sir2 ortholog, SIRT2, is an NAD⁺-dependent tubulin deacetylase. *Mol Cell*. 2003; 11:437–444. [PubMed: 12620231]
59. Beirowski B, et al. Sir-two-homolog 2 (Sirt2) modulates peripheral myelination through polarity protein Par-3/atypical protein kinase C (aPKC) signaling. *Proc Natl Acad Sci USA*. 2011; 108:E952–961. [PubMed: 21949390]
60. Jiang W, et al. Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase. *Mol Cell*. 2011; 43:33–44. [PubMed: 21726808]
61. Jing E, Gesta S, Kahn CR. SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. *Cell Metab*. 2007; 6:105–114. [PubMed: 17681146]
62. Nasrin N, et al. SIRT4 regulates fatty acid oxidation and mitochondrial gene expression in liver and muscle cells. *J Biol Chem*. 2010; 285:31995–32002. [PubMed: 20685656]
63. Schwer B, et al. Neural sirtuin 6 (Sirt6) ablation attenuates somatic growth and causes obesity. *Proc Natl Acad Sci USA*. 2010; 107:21790–21794. [PubMed: 21098266]
64. Vakhrusheva O, et al. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. *Circ Res*. 2008; 102:703–710. [PubMed: 18239138]
65. Nemoto S, Fergusson MM, Finkel T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. *Science*. 2004; 306:2105–2108. [PubMed: 15604409]


66. Coste A, et al. The genetic ablation of SRC-3 protects against obesity and improves insulin sensitivity by reducing the acetylation of PGC-1{alpha}. *Proc Natl Acad Sci USA*. 2008; 105:17187–17192. [PubMed: 18957541]
67. Noriega LG, et al. CREB and ChREBP oppositely regulate SIRT1 expression in response to energy availability. *EMBO Rep*. 2011
68. Hayashida S, et al. Fasting promotes the expression of SIRT1, an NAD⁺-dependent protein deacetylase, via activation of PPARalpha in mice. *Mol Cell Biochem*. 2010; 339:285–292. [PubMed: 20148352]
69. Han L, et al. SIRT1 is regulated by a PPAR{gamma}-SIRT1 negative feedback loop associated with senescence. *Nucleic Acids Res*. 2010; 38:7458–7471. [PubMed: 20660480]
70. Okazaki M, et al. PPARbeta/delta regulates the human SIRT1 gene transcription via Sp1. *Endocr J*. 2010; 57:403–413. [PubMed: 20160399]
71. Chen WY, et al. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. *Cell*. 2005; 123:437–448. [PubMed: 16269335]
72. Zhang Q, et al. Metabolic regulation of SIRT1 transcription via a HIC1:CtBP corepressor complex. *Proc Natl Acad Sci USA*. 2007; 104:829–833. [PubMed: 17213307]
73. Bai P, et al. PARP-2 Regulates SIRT1 Expression and Whole-Body Energy Expenditure. *Cell Metab*. 2011; 13:450–460. [PubMed: 21459329]
74. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. *Proc Natl Acad Sci USA*. 2008; 105:13421–13426. [PubMed: 18755897]
75. Lee J, et al. A pathway involving farnesoid X receptor and small heterodimer partner positively regulates hepatic sirtuin 1 levels via microRNA-34a inhibition. *J Biol Chem*. 2010; 285:12604–12611. [PubMed: 20185821]
76. Rane S, et al. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. *Circ Res*. 2009; 104:879–886. [PubMed: 19265035]
77. Giralt A, et al. Peroxisome proliferator-activated receptor-gamma coactivator-1alpha controls transcription of the Sirt3 gene, an essential component of the thermogenic brown adipocyte phenotype. *J Biol Chem*. 2011; 286:16958–16966. [PubMed: 21454513]
78. Sasaki T, et al. Phosphorylation regulates SIRT1 function. *PLoS ONE*. 2008; 3:e4020. [PubMed: 19107194]
79. Nasrin N, et al. JNK1 phosphorylates SIRT1 and promotes its enzymatic activity. *PLoS ONE*. 2009; 4:e8414. [PubMed: 20027304]
80. Guo X, Williams JG, Schug TT, Li X. DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1. *J Biol Chem*. 2010; 285:13223–13232. [PubMed: 20167603]
81. Yang Y, et al. SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. *Nat Cell Biol*. 2007; 9:1253–1262. [PubMed: 17934453]
82. Bai P, et al. PARP-1 Inhibition Increases Mitochondrial Metabolism through SIRT1 Activation. *Cell Metab*. 2011; 13:461–468. [PubMed: 21459330] [**This report demonstrates how the interplay between different NAD⁺ consumers can regulate SIRT1 activity.**]
83. Kim EJ, Kho JH, Kang MR, Um SJ. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. *Mol Cell*. 2007; 28:277–290. [PubMed: 17964266]
84. Picard F, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. *Nature*. 2004; 429:771–776. [PubMed: 15175761]
85. Kim JE, Chen J, Lou Z. DBC1 is a negative regulator of SIRT1. *Nature*. 2008; 451:583–586. [PubMed: 18235501]
86. Zhao W, et al. Negative regulation of the deacetylase SIRT1 by DBC1. *Nature*. 2008; 451:587–590. [PubMed: 18235502]
87. Escande C, et al. Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. *J Clin Invest*. 2010; 120:545–558. [PubMed: 20071779]
88. Mulligan P, et al. A SIRT1-LSD1 corepressor complex regulates Notch target gene expression and development. *Mol Cell*. 2011; 42:689–699. [PubMed: 21596603]

89. Chen D, et al. Tissue-specific regulation of SIRT1 by calorie restriction. *Genes Dev.* 2008; 22:1753–1757. [PubMed: 18550784]
90. Kim HJ, et al. Metabolomic analysis of livers and serum from high-fat diet induced obese mice. *J Proteome Res.* 2011; 10:722–731. [PubMed: 21047143]
91. Collins PB, Chaykin S. The management of nicotinamide and nicotinic acid in the mouse. *J Biol Chem.* 1972; 247:778–783. [PubMed: 4333514]
92. Bieganowski P, Brenner C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD⁺ in fungi and humans. *Cell.* 2004; 117:495–502. [PubMed: 15137942]
93. Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide Mononucleotide, a Key NAD(+) Intermediate, Treats the Pathophysiology of Diet- and Age-Induced Diabetes in Mice. *Cell Metab.* 2011; 14:528–536. [PubMed: 21982712]
94. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. *Nat Rev Mol Cell Biol.* 2006; 7:517–528. [PubMed: 16829982]
95. Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. *Mol Cell.* 2010; 39:8–24. [PubMed: 20603072]
96. Barbosa MT, et al. The enzyme CD38 (a NAD glycohydrolase, EC 3.2.2.5) is necessary for the development of diet-induced obesity. *Faseb J.* 2007; 21:3629–3639. [PubMed: 17585054]
97. Dong M, et al. Design, synthesis and biological characterization of novel inhibitors of CD38. *Org Biomol Chem.* 2011; 9:3246–3257. [PubMed: 21431168]
98. Lavu S, Boss O, Elliott PJ, Lambert PD. Sirtuins--novel therapeutic targets to treat age-associated diseases. *Nat Rev Drug Discov.* 2008; 7:841–853. [PubMed: 18827827]
99. Pearson KJ, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. *Cell Metab.* 2008; 8:157–168. [PubMed: 18599363]
100. Timmers S, et al. Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans. *Cell Metab.* 2011; 14:612–622. [PubMed: 22055504] **[This paper is the first description of resveratrol treatment in humans, mimicking the effects of calorie restriction by showing improved (mitochondrial) metabolism in obese subjects.]**
101. Milne JC, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. *Nature.* 2007; 450:712–716. [PubMed: 18046409]
102. Pacholec M, et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. *J Biol Chem.* 2010; 285:8340–8351. [PubMed: 20061378]
103. Beher D, et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. *Chem Biol Drug Des.* 2009; 74:619–624. [PubMed: 19843076]
104. Um JH, et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. *Diabetes.* 2010; 59:554–563. [PubMed: 19934007]
105. Hawley SA, et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. *Cell Metab.* 2010; 11:554–565. [PubMed: 20519126]
106. Zheng J, Ramirez VD. Inhibition of mitochondrial proton F₀F₁-ATPase/ATP synthase by polyphenolic phytochemicals. *Br J Pharmacol.* 2000; 130:1115–1123. [PubMed: 10882397]
107. Bouche C, Serdy S, Kahn CR, Goldfine AB. The cellular fate of glucose and its relevance in type 2 diabetes. *Endocr Rev.* 2004; 25:807–830. [PubMed: 15466941]
108. Liu Y, et al. A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. *Nature.* 2008; 456:269–273. [PubMed: 18849969] **[This study describes how SIRT1, CRTC2 and FOXO1 are temporally regulated during fasting.]**
109. Frescas D, Valenti L, Accili D. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. *J Biol Chem.* 2005; 280:20589–20595. [PubMed: 15788402]
110. Herzog B, Hall RK, Wang XL, Waltner-Law M, Granner DK. Peroxisome proliferator-activated receptor gamma coactivator-1alpha, as a transcription amplifier, is not essential for basal and hormone-induced phosphoenolpyruvate carboxykinase gene expression. *Molecular Endocrinology.* 2004; 18:807–819. [PubMed: 15044597]

111. Bordone L, et al. SIRT1 transgenic mice show phenotypes resembling calorie restriction. *Aging Cell*. 2007; 6:759–767. [PubMed: 17877786]
112. Rutanen J, et al. SIRT1 mRNA expression may be associated with energy expenditure and insulin sensitivity. *Diabetes*. 2010; 59:829–835. [PubMed: 20107110]
113. Wang RH, et al. Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. *J Clin Invest*. 2011 [**This article demonstrates that hepatic SIRT1 deficiency causes whole-body insulin resistance due to hyperglycemia induced oxidative stress.**]
114. Purushotham A, et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. *Cell Metab*. 2009; 9:327–338. [PubMed: 19356714] [**This study shows that hepatic SIRT1 deletion increases susceptibility to hepatic steatosis and body weight gain upon high-fat feeding.**]
115. Rodgers JT, Puigserver P. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. *Proc Natl Acad Sci USA*. 2007; 104:12861–12866. [PubMed: 17646659]
116. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. *Cell Metab*. 2006; 3:177–185. [PubMed: 16517405]
117. Lim JH, et al. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. *Mol Cell*. 2010; 38:864–878. [PubMed: 20620956]
118. Finley LW, et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. *Cancer Cell*. 2011; 19:416–428. [PubMed: 21397863]
119. Muoio DM, Newgard CB. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. *Nat Rev Mol Cell Biol*. 2008; 9:193–205. [PubMed: 18200017]
120. Moynihan KA, et al. Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. *Cell Metab*. 2005; 2:105–117. [PubMed: 16098828]
121. Bordone L, et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. *PLoS Biol*. 2006; 4:e31. [PubMed: 16366736]
122. Ahuja N, et al. Regulation of insulin secretion by SIRT4, a mitochondrial ADP-ribosyltransferase. *J Biol Chem*. 2007; 282:33583–33592. [PubMed: 17715127]
123. Schug TT, Li X. Sirtuin 1 in lipid metabolism and obesity. *Ann Med*. 2011; 43:198–211. [PubMed: 21345154]
124. Strable MS, Ntambi JM. Genetic control of de novo lipogenesis: role in diet-induced obesity. *Crit Rev Biochem Mol Biol*. 2010; 45:199–214. [PubMed: 20218765]
125. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. *J Clin Invest*. 2002; 109:1125–1131. [PubMed: 11994399]
126. Li X, et al. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. *Mol Cell*. 2007; 28:91–106. [PubMed: 17936707]
127. Ponugoti B, et al. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. *J Biol Chem*. 2010; 285:33959–33970. [PubMed: 20817729]
128. Walker AK, et al. Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. *Genes Dev*. 2010; 24:1403–1417. [PubMed: 20595232]
129. Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschop MH. Sirt1 protects against high-fat diet-induced metabolic damage. *Proc Natl Acad Sci USA*. 2008; 105:9793–9798. [PubMed: 18599449]
130. Wang RH, Li C, Deng CX. Liver steatosis and increased ChREBP expression in mice carrying a liver specific SIRT1 null mutation under a normal feeding condition. *Int J Biol Sci*. 2010; 6:682–690. [PubMed: 21103071]
131. Kim HS, et al. Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. *Cell Metab*. 2010; 12:224–236. [PubMed: 20816089]
132. Wang P, Mariman E, Renes J, Keijzer J. The secretory function of adipocytes in the physiology of white adipose tissue. *J Cell Physiol*. 2008; 216:3–13. [PubMed: 18264975]

133. Heikkinen S, Auwerx J, Argmann CA. PPARgamma in human and mouse physiology. *Biochim Biophys Acta*. 2007; 1771:999–1013. [PubMed: 17475546]
134. Wang F, Tong Q. SIRT2 suppresses adipocyte differentiation by deacetylating FOXO1 and enhancing FOXO1's repressive interaction with PPARgamma. *Mol Biol Cell*. 2009; 20:801–808. [PubMed: 19037106]
135. Schreurs M, Kuipers F, van der Leij FR. Regulatory enzymes of mitochondrial beta-oxidation as targets for treatment of the metabolic syndrome. *Obes Rev*. 2010; 11:380–388. [PubMed: 19694967]
136. Xu F, et al. Lack of SIRT1 (Mammalian Sirtuin 1) activity leads to liver steatosis in the SIRT1+/- mice: a role of lipid mobilization and inflammation. *Endocrinology*. 2010; 151:2504–2514. [PubMed: 20339025]
137. Li Y, et al. Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver. *FASEB J*. 2011; 25:1664–1679. [PubMed: 21321189]
138. Ajmo JM, Liang X, Rogers CQ, Pennock B, You M. Resveratrol alleviates alcoholic fatty liver in mice. *Am J Physiol Gastrointest Liver Physiol*. 2008; 295:G833–842. [PubMed: 18755807]
139. Yamazaki Y, et al. Treatment with SRT1720, a SIRT1 Activator, Ameliorates Fatty Liver with Reduced Expression of Lipogenic Enzymes in MSG Mice. *Am J Physiol Endocrinol Metab*. 2009
140. Yamamoto H, et al. NCoR1 is a conserved physiological modulator of muscle mass and oxidative function. *Cell*. 2011; 147:827–839. [PubMed: 22078881] [**This paper shows that reduced corepressors activity can improve metabolism similarly to enhanced coactivator activity.**]
141. Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. *Endocr Rev*. 2006; 27:728–735. [PubMed: 17018837]
142. Fernandez-Marcos PJ, Auwerx J. Regulation of PGC-1alpha, a nodal regulator of mitochondrial biogenesis. *Am J Clin Nutr*. 2011; 93:884S–890. [PubMed: 21289221]
143. Jager S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. *Proc Natl Acad Sci USA*. 2007; 104:12017–12022. [PubMed: 17609368]
144. Gonzalez AA, Kumar R, Mulligan JD, Davis AJ, Saupe KW. Effects of aging on cardiac and skeletal muscle AMPK activity: basal activity, allosteric activation, and response to in vivo hypoxemia in mice. *Am J Physiol Regul Integr Comp Physiol*. 2004; 287:R1270–1275. [PubMed: 15284083]
145. Schenk S, et al. Sirt1 enhances skeletal muscle insulin sensitivity in mice during caloric restriction. *J Clin Invest*. 2011; 121:4281–4288. [PubMed: 21985785] [**This paper demonstrates that calorie restriction-induced insulin sensitivity is mediated by SIRT1 in skeletal muscle in mice.**]
146. Palacios OM, et al. Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1alpha in skeletal muscle. *Aging*. 2009; 1:771–783. [PubMed: 20157566]
147. Philp A, et al. Sirtuin 1 (SIRT1) Deacetylase Activity Is Not Required for Mitochondrial Biogenesis or Peroxisome Proliferator-activated Receptor- γ Coactivator-1 α (PGC-1 α) Deacetylation following Endurance Exercise. *J Biol Chem*. 2011; 286:30561–30570. [PubMed: 21757760]
148. Canto C, Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. *Curr Opin Lipidol*. 2009; 20:98–105. [PubMed: 19276888]
149. Tissenbaum HA, Guarente L. Increased dosage of a sir-2 gene extends lifespan in *Caenorhabditis elegans*. *Nature*. 2001; 410:227–230. [PubMed: 11242085]
150. Rogina B, Helfand SL. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. *Proc Natl Acad Sci USA*. 2004; 101:15998–16003. [PubMed: 15520384]
151. Bass TM, Weinkove D, Houthoofd K, Gems D, Partridge L. Effects of resveratrol on lifespan in *Drosophila melanogaster* and *Caenorhabditis elegans*. *Mech Ageing Dev*. 2007; 128:546–552. [PubMed: 17875315]
152. Kaeberlein M, Powers RW. 3rd. Sir2 and calorie restriction in yeast: a skeptical perspective. *Ageing Res Rev*. 2007; 6:128–140. [PubMed: 17512264]

153. Burnett C, et al. Absence of effects of Sir2 overexpression on lifespan in *C. elegans* and *Drosophila*. *Nature*. 2011; 477:482–485. [PubMed: 21938067] [**This study shows that Sir2/sir-2.1 overexpression is not sufficient to extend lifespan in flies and worms.**]
154. Viswanathan M, Guarente L. Regulation of *Caenorhabditis elegans* lifespan by sir-2.1 transgenes. *Nature*. 2011; 477:E1–2. [PubMed: 21938026]
155. Li Y, Xu W, McBurney MW, Longo VD. SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. *Cell metabolism*. 2008; 8:38–48. [PubMed: 18590691]
156. Herranz D, et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. *Nat Commun*. 2010; 1:3. [PubMed: 20975665] [**This report demonstrates that Sirt1 overexpression in mice improves healthy aging, but does not extend lifespan.**]
157. Flachsbart F, et al. Sirtuin 1 (SIRT1) sequence variation is not associated with exceptional human longevity. *Exp Gerontol*. 2006; 41:98–102. [PubMed: 16257164]
158. Bastin J, Lopes-Costa A, Djouadi F. Exposure to resveratrol triggers pharmacological correction of fatty acid utilization in human fatty acid oxidation-deficient fibroblasts. *Hum Mol Genet*. 2011; 20:2048–2057. [PubMed: 21378393]

BOX1**Enzymatic activity of sirtuins**

Although sirtuins were originally described as histone deacetylases (part **a**, removing an acetyl moiety from a histone/protein), a shift is taking place in how the field approaches the sirtuin enzymatic activity. Not only did the range of deacetylase targets broaden beyond histones, to include many transcription factors and enzymes (reviewed in 5,24,30), but also SIRT4 and SIRT6 were described to act as ADP-ribosyl

transferases^{17,18} (part **b**, transferring an ADP-ribose moiety onto a protein). Two recent papers^{22,23} now describe SIRT5 to possess demalonylation (part **c**, removing a malonyl moiety from a protein) and desuccinylation (part **d**, removing a succinyl moiety from a protein) activity. These new functions expose the possibility that sirtuins might in fact function as protein deacylases (removing any acyl moiety from a protein), with a wide variety of target proteins. The acetyl, malonyl, or succinyl moiety that is removed during such deacylase reaction, could also be considered ADP-ribosylated during this process²³. It is tempting to speculate that the actual function of sirtuin is not to deacetylate proteins, but rather to function as ADP-ribosyl transferase or deacylase, using either an unmodified protein as a target — e.g. ADP-ribosylation activity of SIRT4 and SIRT6 — or a protein modified with either an acetyl-, malonyl-, or succinyl moiety. This would in fact describe a more general activity that is true for all sirtuins, without discrimination of the actual target.

BOX 2**SIRT1 and longevity – a shift from life-span towards health-span**

The yeast Sir2 was described as a longevity protein⁷, and with time also worm *sir-2.1*¹⁴⁹ and fly Sir2150 were implicated in lifespan regulation and thought to mediate the beneficial effects of caloric restriction on lifespan³. This role of sirtuins was seemingly corroborated by the beneficial effects of the sirtuin-activating compound resveratrol on yeast lifespan⁹, but other studies in *Drosophila melanogaster* and *Caenorhabditis elegans* have cast a shadow of doubt on the possibility that sirtuins mediate the effects of resveratrol and caloric restriction on longevity^{151,152}. Furthermore, recent work demonstrates that the effect of overexpression of worm *sir-2.1* or fly *Sir2* on longevity is limited at best^{153,154}.

Evidence for a role of SIRT1 in longevity is not clear in mammals either. Arguing for a role of *Sirt1* in CR-mediated longevity, *Sirt1*^{-/-} mice do not show lifespan extension on a CR regimen¹⁵⁵. SIRT1 transgenic mice display reduced cancer risk and are protected against metabolic dysfunction associated with aging, but do not show increased lifespan¹⁵⁶. Mice treated with resveratrol⁹⁹ or the synthetic sirtuin activator SRT1720³⁷ show increased lifespan, but only when metabolically stressed with a high-fat diet. However, it should be mentioned that there is concern that both resveratrol and SRT1720 might not target SIRT1 specifically¹⁰². In addition, no genetic association was found between polymorphisms in *Sirt1* and human lifespan¹⁵⁷. Altogether, we hypothesize that SIRT1 activity may not determine natural lifespan, but rather plays a role in health maintenance and stress response, and upon activation extends lifespan or rescues stress-induced reductions in lifespan. Interestingly, SIRT6 is a strong determinant of lifespan, as *Sirt6*^{-/-} mice show signs of accelerated aging¹⁴. Further studies in animal models and humans are needed to explore the effects of the other sirtuin family members on lifespan.




Figure 1. Regulation of sirtuin expression and activity.

a | Various transcription factors regulate sirtuin expression. FOXO1, PPAR α , PPAR β/δ and CREB enhance SIRT1 (in green), whereas PPAR γ , ChREBP, PARP2 and HIC1 repress SIRT1 expression (in red). Only CREB, ChREBP and PARP2 were also shown to possess this activity *in vivo*. *Sirt1* expression is also repressed by the miRNAs miR-34a and miR-199a. **b** | Reversible post-translational modifications affect SIRT1 activity. The cyclinB/Cdk1 complex phosphorylates (P) SIRT1 thereby allowing cell cycle progression. Activation of JNK by reactive oxygen species (ROS) results in SIRT1 phosphorylation and subsequent deacetylation of histone H3, but not p53. Genotoxic stress, for instance by UV light or H₂O₂ exposure, results in desumoylation of SIRT1, inactivating it. Sumoylation (sumo) by a yet unidentified enzyme activates SIRT1. **c** | Complex formation with other proteins influences SIRT1 enzymatic activity. A complex of NCoR1 and SIRT1 blocks the transcriptional activity of PPAR γ . Genotoxic and metabolic (high-fat diet) stress induce DBC1-SIRT1 complex formation, by which DBC1 inactivates SIRT1. Fasting relieves this inactivation. The LSD1-SIRT1 complex represses Notch target gene expression by demethylation and deacetylation of specific histones, but is derepressed by activation of the Notch pathway. Complex formation with AROS activates SIRT1. **d** | Controlling the levels of the cofactor NAD⁺ governs SIRT1 function. NAD⁺ levels are increased by providing precursors nicotinic

acid (NA), nicotinamide (NAM) or nicotinamide riboside (NR), inhibiting its breakdown by means of PARP or CD38 inhibition, or by AMPK activation following energy stress or treatment with the AMPK activator resveratrol. Increased NAD⁺ levels subsequently lead to sirtuin activation.




Figure 2. Overview of sirtuins' role in the regulation of pathways involved in glucose metabolism. Red arrows indicate activating effects whereas blue bars denote inhibiting functions. Colored symbols show metabolic processes, genes or proteins, which are affected by the nuclear function(s) of SIRT1 or SIRT6. The involvement of certain specific sirtuins in the control of particular metabolic pathway is indicated with white oval.




Figure 3. Overview of sirtuins' role in the regulation of lipid metabolism.

Red arrows indicate activating effects whereas blue bars denote inhibiting functions. Colored symbols show metabolic processes, genes or proteins, which are affected by the nuclear function(s) of SIRT1 or SIRT6. The involvement of certain specific sirtuins in the control of particular metabolic pathway is indicated with white oval.




Figure 4. The association of sirtuin activity with metabolic health.

a | Sirtuins influence glucose and lipid metabolism in several tissues. SIRT1 inhibits adipogenesis in 3T3L1 adipocytes. In addition, SIRT1 decreases fat storage by enhances lipolysis through PPAR γ in WAT. In pancreas, SIRT1 increases insulin secretion by repressing the transcription of UCP2. In skeletal muscle, SIRT1 attenuates glycolysis via PGC1 α and enhances lipid utilization by stimulating PGC1 α and PPAR α . In the liver, SIRT1 decreases glycolysis via HIF1 α and PGC1 α and lowers lipid accumulation by suppressing lipid synthesis via SREBP-1c and promoting lipid utilization through PGC1 α and PPAR α . In addition, SIRT1 regulates hepatic glucose production via PGC1 α , CRT2 and FOXO1, although its exact role in this process is under debate. Using SIRT3 whole-body knock-out mice, it has been demonstrated that during energy limitation, SIRT3 suppresses glycolysis via HIF1 α , promotes fatty acid oxidation through LCAD, IDH2 and NDUFA9, protects from ROS by stimulating SOD2 and increases ketone body formation through HMGCS2. Based on in vitro studies, SIRT3 promotes cellular respiration in brown adipocytes via SDH.

b | In response to calorie restriction and exercise, the induction of SIRT1 stimulates mitochondrial activity, leading to improved metabolism and disease prevention. During

energy limitation, low ATP levels activate AMPK, which in turn induces SIRT1 by increasing NAD⁺ levels. SIRT1 increases mitochondrial activity by decreasing acetylation levels of PGC1 α . During calorie excess and sedentary life-style, cellular ATP levels increase, whereas NAD⁺ levels decrease, thereby inhibiting SIRT1. As a result, PGC1 α remains acetylated, which leads to decreased mitochondrial activity, predisposing to the development of metabolic diseases.

Table 1
Sirtuin localization and function.

Sirtuin	Class	Localization	Activity	Targets	References
SIRT1	I	Nuclear, cytosolic	Deacetylation	PGC1 α , FOXO1, FOXO3, p53, NOTCH, NF- κ B, HIF1 α , LXR, FXR, SREBP-1c, and more	5,30,32,33,39,41,42
SIRT2	I	Cytosolic	Deacetylation	Tubulin, PEPCK, FOXO1, PAR-3	58–61
SIRT3	I	Mitochondrial	Deacetylation	LCAD, HMGCS2, SOD2, GDH, IDH2, OXPHOS complexes, and more	46–49,51–57
SIRT4	II	Mitochondrial	ADP-ribosylation	GDH	17
SIRT5	III	Mitochondrial	Deacetylation, demalonylation, desuccinylation	CPS1	21–23
SIRT6	IV	Nuclear	Deacetylation, ADP-ribosylation	H3K9, H3K56	14,18–20,63
SIRT7	IV	Nucleolus	Unknown	unknown	15,64